Published in Eur J Cancer on October 01, 1974
Mycobacterium bovis, BCG, modulation of murine antibody responses: influence of dose and degree of aggregation of live or dead organisms. Br J Exp Pathol (1982) 0.89
Possible role of macrophage-like suppressor cells in the anti-tumour activity of BCG. Br J Cancer (1981) 0.85
Modulation of the immune response by BCG: a review. Yale J Biol Med (1976) 0.82
Further observations on the effect of cyclophosphamide on intratumor and peripheral leukocyte levels. Am J Pathol (1980) 0.75
Active immunotherapy for acute lymphoblastic leukaemia. Lancet (1969) 13.03
Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet (2001) 3.50
Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer (1969) 2.96
The need of a physiologic and pathophysiologic definition of stress. Biomed Pharmacother (2000) 1.93
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst (1990) 1.81
Approaches to the immunological treatment of cancer in man. Br Med J (1969) 1.76
Acute lymphoblastic leukaemia treated with a combination of prednisone, vincristine, and rubidomycin. Value of pathogen-free rooms. Lancet (1967) 1.65
Histopathologic sequence of events in adult mice undergoing lethal graft-versus-host reaction developed across H-2 and/or non-H-2 histocompatibility barriers. Am J Pathol (1979) 1.62
Extensive histological and cytological survey of patients with acute leukaemia in "complete remission". Br Med J (1966) 1.57
Polyphenols: do they play a role in the prevention of human pathologies? Biomed Pharmacother (2002) 1.57
Immunological treatment of leukaemias. Br Med J (1970) 1.47
[Degradation of thymidine by transformed lymphocytes]. Rev Fr Etud Clin Biol (1965) 1.43
New antigens in human leukaemic cells and antibody in the serum of leukaemic patients. Lancet (1967) 1.42
Effect of physiologic vs UV pathogenic stress on immunity reactions and tolerance, via immunocyte traffic and homing. Biomed Pharmacother (2000) 1.40
Hypothetical reasons of the HIV1-AIDS "tritherapy" failure. A challenging model. Biomed Pharmacother (1997) 1.37
The two varieties of lymphoid tissue "reticulosarcomas", histiocytic and histioblastic types. Br J Cancer (1970) 1.36
Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J (1970) 1.32
[Demonstration of the efficacy of active immunotherapy in human acute lymphoblastic leukemia]. Rev Fr Etud Clin Biol (1968) 1.27
Active immunotherapy. Adv Cancer Res (1971) 1.22
The role of immunology in the treatment of leukemias and hematosarcomas. Cancer Res (1967) 1.21
Attempts at immunotherapy of 100 patients with acute lymphoid leukemia: some factors influencing results. Natl Cancer Inst Monogr (1972) 1.20
Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res (1965) 1.19
Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes (2000) 1.17
Phase I pharmacologic study of a new Vinca alkaloid: navelbine. Cancer Lett (1985) 1.13
I. Arginine. Biomed Pharmacother (2002) 1.11
II. Glutamine and glutamate. Biomed Pharmacother (2002) 1.09
An overview of the 1978 international meeting on comparative therapeutic trials. Biomedicine (1978) 1.08
[Active immunotherapy of L 1210 leukemia given after the graft of the tumor]. Rev Fr Etud Clin Biol (1968) 1.08
Seasonal modulation of the circadian time structure of circulating T and natural killer lymphocyte subsets from healthy subjects. J Clin Invest (1988) 1.08
Establishment and characterization of a new human eosinophilic leukemia cell line. Blood (1985) 1.08
T and B lymphocyte markers on the neoplastic cell of 20 patients with acute and 10 patients with chronic lymphoid leukemia. Biomedicine (1974) 1.07
Nonspecific macrophage activation by systemic adjuvants. Evaluation by lysosomal enzyme and in vitro tumoricidal activities. Int Arch Allergy Appl Immunol (1976) 1.06
A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother (1986) 1.04
Attempted adoptive immunotherapy of acute leukaemia by leucocyte transfusions. Lancet (1966) 1.02
Large-amplitude circadian rhythm in helper:suppressor ratio of peripheral blood lymphocytes. Lancet (1983) 1.00
[Chemotherapy of L1210 leukemia: comparison of 7 drugs given either continuously for 20 days, or in a single massive dose, early or late]. Rev Fr Etud Clin Biol (1968) 1.00
[Acute leukemia and various hematosarcomas. Trial treatment with a second derivative of podophyllotoxin (4-demethyl-epipodophyllotoxin beta D ethylidene glucoside VP 16213 or EPE)]. Nouv Presse Med (1974) 0.99
Remission induction with Poly IC in patients with acute lymphoblastic leukaemia (preliminary results). Rev Eur Etud Clin Biol (1970) 0.98
Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoid. Lancet (1982) 0.98
[Therapeutic trials in various hematosarcomas with 4-demethylepipo=dophyllotoxin-beta D thenylidene glucoside (VM 26 or EPT)]. Nouv Presse Med (1974) 0.97
Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep (1982) 0.96
White blood cell transfusions. Isr J Med Sci (1965) 0.96
Genetic exclusion of 14 candidate genes in lipoatropic diabetes using linkage analysis in 10 consanguineous families. J Clin Endocrinol Metab (1997) 0.95
[Hematologic resuscitation. II. Correction of severe leukocyte and immune globulin disorders. The bone marrow graft]. Presse Med (1966) 0.95
Clinical examination of drugs, a scientific and ethical challenge. Biomedicine (1973) 0.95
Methoxy-9-ellipticine lactate. 3. Clinical screening: its action in acute myeloblastic leukaemia. Rev Eur Etud Clin Biol (1970) 0.95
An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy. Cancer Res (1973) 0.94
Strong histocompatibility and cell-mediated cytotoxic effects of a single Mls difference demonstrated using a new congenic mouse strain. Eur J Immunol (1983) 0.94
[Local elective immunotherapy of L 1210 ascitic leukemia. Analysis of factors of its efficacy]. Eur J Cancer (1968) 0.94
The failure of HAART to cure the HIV-1/AIDS complex. Suggestions to add integrase inhibitors as complementary virostatics, and to replace their continuous long combination applications by short sequences differing by drug rotations. Biomed Pharmacother (2001) 0.94
Monoclonal antibodies directed against T cell epitopes presented by class I MHC antigens. Int Immunol (1993) 0.93
Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother (1988) 0.93
Efficacy of and errors in randomized multicenter trials. A review of 230 clinical trials. Biomed Pharmacother (1983) 0.92
Powerful new inhibitor of murine leukaemia and sarcoma viruses. Nature (1970) 0.92
[Angioimmunoblastic adenopathies]. Nouv Presse Med (1976) 0.92
Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. Cancer Res (1989) 0.92
[Treatment of acute lymphoblastic leukemia during a remission by irradiation of the central nervous system and subsequent administration of 8 chemotherapeutic agents]. Sem Hop (1966) 0.91
[Revelation of leukemigenic virus by means of hematopoietic chimerism. Allogenic chimerism in mice]. C R Acad Sci Hebd Seances Acad Sci D (1966) 0.91
[A new combination of methotrexate and folinic acid for cancer treatment (acute leukemia and solid tumors)]. Presse Med (1969) 0.91
Bone marrow transplantation in man. Transplant Proc (1969) 0.90
Histologic reactions of the thymus, spleen, liver and lymph nodes to intravenous and subcutaneous BCG injections. Biomedicine (1975) 0.89
[Use of a steady-flow blood cell separator for the separation of blood lymphocytes]. Nouv Rev Fr Hematol (1969) 0.89
Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol (1990) 0.89
[Fibrinogenopenia syndrome during acute leukemia. Determining role of leukemic cells. "In vitro" study of their fibrinolytic capacity]. Rev Fr Etud Clin Biol (1966) 0.88
Pathogen-free isolation unit--three years' experience. Br Med J (1969) 0.88
A lymphocyte-inhibiting factor (chalone?) extracted from thymus: immunosuppressive effects. Natl Cancer Inst Monogr (1973) 0.88
Involvement of IFN-gamma and transforming growth factor-beta in graft-vs-host reaction-associated immunosuppression. J Immunol (1993) 0.87
T lymphocyte specificity of a lymphocyte-inhibiting factor (chalone) extracted from the thymus. Eur J Immunol (1973) 0.87
Are the neoantigens induced by chemical carcinogens or by leukaemogenic viruses particular to cancer cells? Transplant Proc (1969) 0.86
Bone marrow graft in man after conditioning by antilymphocytic serum. Transplant Proc (1971) 0.86
Mismatching for minor histocompatibility antigens in bone marrow transplantation: consequences for the development and control of severe graft-versus-host disease. Transplant Proc (1979) 0.86
Some effects of a partially purified lymphocyte-inhibiting factor from calf thymus. Transplantation (1972) 0.85
Clinical significance and prognostic value of the T-B immunological classification of human primary acute lymphoid leukaemias. Lancet (1977) 0.85
Inhibition of graft-versus-host reaction by preincubation of the graft with a thymic extract (lymphocyte chalone). Transplantation (1973) 0.85
Parameters involved in the induction and abrogation of the lethal graft-versus-host reaction directed against non-H-2 antigens. Immunol Rev (1985) 0.85
[Trial treatment of chronic myeloid leukemia with 3 new chemotherapeutic agents: dibromomannitol, hydroxyurea and desacetamidocolchicine]. Sem Hop (1966) 0.84
Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV. Br J Cancer Suppl (1975) 0.84
Preliminary result of a new protocol for the active immunotherapy of acute lymphoblastic leukaemia: inhibition of the immunotherapeutic effect by Vincristine or Adamantadine. Rev Eur Etud Clin Biol (1971) 0.84
[Study of the immunologic restoration of allogenic hematopoietic radiation chimeras]. Rev Fr Etud Clin Biol (1968) 0.84
Immunogenetic and immunological problems of allogeneic haemopoietic radio-chimaeras in man. Scand J Haematol (1967) 0.84
Cytology in the classification of diffuse non-leukaemic malignant lymphomata (lympho- and reticulosarcomata). Br J Cancer Suppl (1975) 0.83
Effects of Bacillus Calmette-Guérin and levamisole on immune responses in young adult and age-immunodepressed mice. Cancer Treat Rep (1978) 0.83
Evidence for a lymphocytic chalone. Rev Eur Etud Clin Biol (1970) 0.83
[Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial]. Nouv Presse Med (1979) 0.83
BCG in cancer immunotherapy: experimental and clinical trials of its use in treatment of leukemia minimal and or residual disease. Natl Cancer Inst Monogr (1973) 0.83
[Immunologic approaches tthe treatmentof leukemia. 1st results in man]. Nouv Rev Fr Hematol (1968) 0.82
The effects of certain immunity systemic advuvants, PHA, and human gamma globulin on the thymic cortex of mice: a light and electron microscope study. Biomedicine (1976) 0.82
Hyperthermia-induced cell death by apoptosis in myeloma cells. Biomed Pharmacother (2001) 0.82
Leukopenic chronic T cell leukemia mimicking hairy cell leukemia: association with human retroviruses. Blood (1986) 0.82
Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment. Cancer Detect Prev (1986) 0.81
A four-day subrenal capsule assay for testing the effectiveness of anticancer drugs against human tumors. Cancer Res (1984) 0.81
[Extraction and purification of tumoral neo-antigens obtained from splenic cells and serum of mice with Charolotte Friend's leukemia]. Rev Fr Etud Clin Biol (1968) 0.81
New experimental and clinical data on leukaemia immunotherapy. Proc R Soc Med (1975) 0.81